ESTRO 2024 - Abstract Book

S1613

Clinical - Lung

ESTRO 2024

Table 1 – Population and tumor characteristics of the study cohort

LC rates at 1-year were 78.2% (95%CI 55.0-90.4%) for the overall population and 91.7% (95%CI 53.9-98.8%) in the tumor size ≤35mm group versus 57.7% (95%CI 22.1 -81.9%) for tumor size >35mm. OS rates at 1-year were 69.7% (95%CI 51.0- 82.4%). No grade ≥3 toxicities were reported.